Filter Results

Clinical Studies

Closed for Enrollment

  • Epsilon Aminocaproic Acid for the Reduction of Blood Loss in Total Hip Arthroplasty Scottsdale/Phoenix, Ariz., Jacksonville, Fla.

    You are being asked to take part in this research study because you are scheduled to have total hip replacement (arthroplasty) surgery. The goal of this study is to evaluate the effectiveness of the drug, epsilon Aminocaproic Acid (EACA), in decreasing the need for patients to receive blood after surgery. Currently, EACA is approved by the Federal Drug Administration (FDA) to treat a patient who is bleeding. The investigators plan to use EACA to prevent bleeding during and after surgery; use of this drug as a means of preventing bleeding is not currently approved by the FDA.